NetScientific PLC ProAxsis Showcases ProteaseTag® Research at NACFC
30 October 2017 - 6:00PM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
30 October 2017
NetScientific plc
("NetScientific" or the "Company" or the "Group")
ProAxsis to Showcase ProteaseTag(R) abstracts at 2017 North
American Cystic Fibrosis Conference
London, UK - October 30(th) 2017 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, notes the announcement by portfolio
company ProAxsis, that it will be presenting further data on its
ProteaseTag(R) technology in two poster sessions at the North
American Cystic Fibrosis Conference, which takes place between
November 1st - 5th in Indianapolis. The first paper, concerning
sputum storage, enables an increase in flexibility for transporting
patient samples from trial site to lab. The second paper, which
analyses exhaled breath condensate, increases the range of
potential research applications for ProAxsis' CE marked NE
Immunoassay. Both papers facilitate a greater scope of research
applications for ProAxsis' NE Immunoassay.
Commenting on the news, Francois Martelet, Chief Executive
Officer of NetScientific and Chairman of ProAxsis, said: "We are
delighted that ProAxsis' ProteaseTag(R) technology is increasingly
utilised in high-impact respiratory health research, indicating its
potential to become a leader in the field. The findings presented
at the highly regarded NACF Conference, demonstrate the clinical
relevance of ProAxsis technology in cystic fibrosis and will
support its move into its commercialisation phase."
NetScientific holds a 57% stake on a fully diluted basis in
ProAxsis.
The full text of the announcement from ProAxsis can be found
below.
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / netscientific@consilium-comms.com
Jessica Hodgson /
Chris Welsh / Laura
Thornton
Stifel Nicolaus Europe Tel: +44 (0) 20 7710 7600
Limited (NOMAD and Broker)
Jonathan Senior / David
Arch / Ben Maddison
ProAxsis to Showcase ProteaseTag(R) abstracts at 2017 North
American Cystic Fibrosis Conference Date: October 30th, 2017
ProAxsis will be presenting further data on its ProteaseTag(R)
technology, at the North American Cystic Fibrosis Conference, which
takes place between November 1st - 5th in Indianapolis. Dr Charlene
Robb will be presenting a poster entitled "Do sputum storage
conditions impact on the quantification of active neutrophil
elastase, interleukin-8, interleukin-6 and tumour necrosis
factor-<ALPHA>?" on Thursday November 2nd between 11.15am and
1.45pm (Poster Number 288).
In addition, the team at the Royal Brompton Hospital in London,
one of the largest CF expert centres in Europe, will be presenting
the first data on the use of the ProteaseTag(R) Active NE
Immunoassay to measure active neutrophil elastase in exhaled breath
condensate:
Active Neutrophil Elastase can be detected in Exhaled Breath
Condensate in patients with Cystic Fibrosis
C74-ADVANCES IN TRANSLATIONAL COPD
Thematic Poster Session
TUESDAY, MAY 23, 2017
9:15 AM - 4:15 PM
Jane Davies, Professor in Paediatric Respirology &
Experimental Medicine at the National Heart and Lung Institute and
an Honorary Consultant in Paediatric Respiratory Medicine at the
Royal Brompton & Harefield NHS Foundation Trust, said "To our
knowledge this is the first study to report NE in EBC in CF
patients; whilst the method requires further optimisation, we
believe this could be a promising avenue for monitoring of patients
at early stages of disease, such as children."
Dr David Ribeiro, CEO of ProAxsis, said: "This is the 31st
annual NACF Conference, which brings together scientists,
clinicians and caregivers from around the world to discuss and
share ideas on the latest advances in CF research. The work by Dr
Robb and colleagues provides further data for researchers
conducting clinical trials worldwide who need to collect, transport
and analyse sputum samples for inflammatory biomarkers such as
active neutrophil elastase. The 19-patient study conducted at the
Royal Brompton Hospital opens up the possibility of utilising the
ProAxsis technology for airway monitoring in patients unable to
expectorate sputum. We believe these latest findings on our
ProteaseTag(R) technology will be of great interest to the CF
community. "
To find out how ProAxsis can support the measurement of active
protease biomarkers of disease, or for any further queries, please
contact info@proaxsis.com.
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
About ProAxsis Limited:
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of
diseases. Its first immunoassay measures active neutrophil
elastase, a leading indicator of infection and inflammation in
patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary
Disease (COPD) and bronchiectasis, and an important drug target. A
rapid point-of-care test for measuring neutrophil elastase, called
NEATstik(R), was registered with a CE Mark in September 2017. The
laboratory-based immunoassays and point-of-care tests being
developed by ProAxsis incorporate patented ProteaseTags(R); smart
molecules which trap an active protease within a complex biological
sample and enable a visual readout of its presence. ProteaseTags(R)
provide a unique tool to identify and quantify active protease
biomarkers and will assist in the clinical validation of new
therapeutics.
ProAxsis is part of the NetScientific Group and is one of the
Group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABIBDGBDDBGRC
(END) Dow Jones Newswires
October 30, 2017 03:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024